Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alx Oncology Holdings Inc
(NQ:
ALXO
)
1.430
+0.050 (+3.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Alx Oncology Holdings Inc
< Previous
1
2
Next >
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
September 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
September 04, 2024
Clinical study is evaluating ALX Oncology’s investigational CD47-blocking therapeutic with Sanofi’s approved CD38 monoclonal antibody in patients with multiple myeloma
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 08, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Holdings Inc. (NASDAQ: ALXO) Leading the Way in Friday Trading Based on Percentage Gain
December 08, 2023
Via
Investor Brand Network
ALX Oncology Appoints Alan Sandler, M.D., to Board of Directors
August 06, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Topline Data From ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Improves Tumor Response in Patients With HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Host Investor Call and Webcast to Share Topline Data Results From ASPEN-06 Phase 2 Clinical Trial of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
July 31, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Presents First Evorpacept Combination Data with an Antibody-Drug Conjugate from Phase 1 ASPEN-07 Clinical Trial in Patients with Advanced Bladder Cancer
June 02, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Participation in the Jefferies Global Healthcare Conference
May 29, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Appoints Allison Dillon as Chief Business Officer
May 07, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer
April 30, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Two Evorpacept Abstracts Accepted for Poster Presentation at 2024 ASCO Annual Meeting
April 24, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
April 09, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 07, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting
March 05, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces November Investor Conference Participation
November 01, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Closing of Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
October 10, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Pricing of Public Offering
October 05, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces Proposed Public Offering
October 04, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Holdings Inc. (NASDAQ: ALXO) is One of Tuesday Morning’s Most Active Stocks
October 03, 2023
Via
Investor Brand Network
ALX Oncology Reports Positive Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
October 03, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology to Host Investor Call and Webcast on October 3, 2023 to Share Interim Phase 2 ASPEN-06 Clinical Trial Results of Evorpacept for the Treatment of Advanced HER2-Positive Gastric Cancer
October 02, 2023
From
ALX Oncology
Via
GlobeNewswire
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
Via
Investor Brand Network
Exposures
Product Safety
Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation
September 20, 2023
EQNX::TICKER_START (NASDAQ:GNPX),(OTCQX:RHHBY),(NASDAQ:JAZZ),(NASDAQ:ALXO),(NASDAQ:ACHL) EQNX::TICKER_END
Via
FinancialNewsMedia
Exposures
Product Safety
ALX Oncology Realigns Executive Leadership Team
September 06, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Announces September Investor Conference Participation
August 31, 2023
From
ALX Oncology
Via
GlobeNewswire
ALX Oncology Reports Second Quarter 2023 Financial Results and Provides Clinical Program Update
August 10, 2023
From
ALX Oncology
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.